Serge Kemps – CEO, Nipro Europe
Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish…
Address: Namur Office Park
Avenue des dessus de Lives, 6
5101 NAMUR-LOYERS,Belgium
Tel: +32(0)81/33.28.50
Web: http://www.investinwallonia.be/?lang=en
Wallonia’s economy is very focused on the global market and it is one of the largest exporters per capital worldwide.
To support the establishment of prospective foreign investors, the Wallonia government set up a specially trained team in the late 1990s with the objective of assisting all foreign investors in the implementation of their investment project in Wallonia.
This team is called the Office for Foreign Investors (O.F.I) and it forms part of the Agence Wallonne à l’Exportation et aux Investissements étrangers (Wallonia agency for exports and foreign investment).
With the support of public and private players, O.F.I. assists at all stages in successfully establishing businesses in Wallonia by providing invaluable advice in the following spheres: choice of location, grant schemes, tax regime, recruitment and training of staff, project financing arrangements.
Grant schemes, Tax regime, Recruitment and Training of staff, Project financing
Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish…
Karel van de Sompel of GIBBIS – the pluralistic federation of the public and private social-profit healthcare sector within the Brussels area – outlines the scope and aims of the…
Benelux is a crucial cluster for Bristol Myers Squibb (BMS), which recently started construction of its first European CAR-T cell therapy production centre at the Leiden Bio Science Park. Sally…
Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far…
Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus…
Ahead of the much-discussed implementation of an EU-wide legislative framework on joint clinical assessments in 2025, Merck’s Nikola Vesic outlines the scope and aims of the reform and highlights some…
Belgium is a key country for Sanofi in Europe as home to its Geel production site, in which almost EUR one billion has been invested over the past 15 years,…
Stephan Van Nieuwenhove of Finnish national champion Orion Pharma outlines the company’s entrance into the Benelux markets, the significance of the recent acquisition of Belgian animal health firm Inovet BV,…
Diane Kleinermans leads the reimbursement commission at Belgium’s medicines payer, the National Institute for Health and Disability Insurance (NIHDI). With Belgium currently undergoing a landmark reform of its reimbursement procedure,…
Alexander Alonso, GM of medtech giant BD’s Benelux affiliate explains the impact of the COVID-19 pandemic on its operations, the company’s 2025 strategy, and some of the most significant recent…
Speaking exclusively to PharmaBoardroom, Pedro Facon outlines the scope and aims of the new medicines roadmap that NIHDI has recently presented to the Belgian Ministry of Health following extensive stakeholder…
An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She…
See our Cookie Privacy Policy Here